Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Recombinant Norovirus Vaccine in Children Aged 6 Weeks to 13 Years
NCT06524947Phase 3Active, not recruiting
- Sponsor
- Zhifei Biological
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent recombinant norovirus vaccine (Pichia pastoris) in norovirus gastroenteritis, sponsored by Zhifei Biological. Started Jul 2024; status: active, not recruiting.
02
Drugs
quadrivalent recombinant norovirus vaccine (Pichia pastoris)
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT06524947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524947.